Semaglutide linked to lower AFib risk—other GLP-1 drugs appear to fall short

Coverage, in order

1. 6h ago
   
   Cardiovascular Business indie study meta-analysis

   Semaglutide linked to lower AFib risk—other GLP-1 drugs appear to fall short

   GLP-1 receptor agonists have been associated with a wide range of potential benefits for patients with and without type 2 diabetes. The team behind this new meta-analysis hoped to learn more about how the popular medications may impact a person's risk of new-onset AFib.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.